Biotech Valuations 2025: Rational Reset or Overlooked Rebound?
As we find ourselves in mid-2025, biotech stocks are echoing the tempered days of 2018, sitting at around 50% below their 2021 highs. This recalibration raises a vital question: are...
As we find ourselves in mid-2025, biotech stocks are echoing the tempered days of 2018, sitting at around 50% below their 2021 highs. This recalibration raises a vital question: are...
